

# Axinn Secures IPR Victory for Par in Challenge to Horizon's Ravicti Patent

A decorative graphic on the right side of the page features a light blue background with a grid pattern. A white, curved, ribbon-like shape with a grid pattern on its surface curves upwards and to the right, partially overlapping the grid.

NEWS | 1 MIN READ

September 29, 2016

On behalf of Par Pharmaceutical, Inc., attorneys from Axinn successfully challenged U.S. Patent No. 8,404,215 via an *inter partes* review (IPR) before the Patent Trials and Appeals Board (PTAB) at the United States Patent and Trademark Office. The '215 patent is listed in FDA's Orange Book for Ravicti (glycerol phenylbutyrate), a brand name drug used to treat urea cycle disorders. On July 26, 2016, the PTAB heard oral argument on the validity of the '215 patent, and on September 29, 2016 the PTAB issued a Final Decision finding all claims unpatentable.

The company that markets Ravicti and owns the '215 patent, Horizon Therapeutics, Inc., had previously asserted the '215 patent against Par in the United States District Court for the Eastern District of Texas. In a separate action in the United States District Court for the District of New Jersey, Horizon has also asserted against Par three closely-related patents in the same family as the unpatentable '215 patent, which claim nearly identical subject matter.

The Axinn team representing Par in the '215 patent IPR consisted of Aziz Burgy and Matthew Murphy.

## Related People

---



Aziz Burgy



Matthew S. Murphy

To subscribe to our publications, [click here](#).

## Featured Insights

- American Bar Association 2025 Asia-Pacific Conference  
**SPEAKING ENGAGEMENT    ANTITRUST**
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference  
**SPONSORSHIP    ANTITRUST**
- GCR Live: Law Leaders Global 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- The 32nd Annual Marketing Partner Forum  
**EVENT**
- SABA North America Corporate Counsel Retreat 2025  
**SPONSORSHIP    ANTITRUST**
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025  
**CLIENT ALERTS    ANTITRUST**
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards  
**AWARDS & RECOGNITIONS    ANTITRUST**
- Merger Remedies Back in Vogue Under Trump  
**MEDIA MENTIONS    ANTITRUST**

- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation

**AXINN VIEWPOINTS      INTELLECTUAL PROPERTY**

- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

**AXINN VIEWPOINTS      INTELLECTUAL PROPERTY**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved